Page 3 - Francesco Muntoni News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Francesco muntoni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Francesco Muntoni Today - Breaking & Trending Today

Delphina prepares for Sardinia reopening in June


9 hours ago
Delphina hotels & resorts will reopen all of its properties in Sardinia from June as Italy bounces back from the Covid-19 pandemic.
Over €15 million has been invested to enhance the offering and the services for families during lockdown.
Recognised as Italy’s Leading Hotel Group at the World Travel Awards last year, Delphina has been involved for almost 30 years in environmental protection projects and in support of local economies.
Francesco Muntoni, founder and president of Delphina, said: “The investments made in the last 18 months are part of our long-term vision, which over the years has led us to grow consistently with an increasingly eco-sustainable offer, which respects the environment and enhances a healthy lifestyle, culture and local food and wine.” ....

Santa Teresa Gallura , Francesco Muntoni , Hotel Group , Hotel Le Palme , Leading Hotel Group , World Travel Awards , Costa Smeralda , Resort Valle , Leading Green Resort , Archipelago Suites , Archipelago Penthouse , Spa Le Dune , Leading Beach Resort , Ravel News , ஹோட்டல் குழு , முன்னணி ஹோட்டல் குழு , உலகம் பயணம் விருதுகள் , உல்லாசப்போக்கிடம் பள்ளத்தாக்கு , முன்னணி பச்சை உல்லாசப்போக்கிடம் , ஸ்பா லெ மணல்மேடு , முன்னணி கடற்கரை உல்லாசப்போக்கிடம் ,

NHS to use world's most expensive drug to treat spinal muscular atrophy


Last modified on Sun 7 Mar 2021 23.37 EST
The world’s most expensive drug, which treats babies and young children with a rare and often fatal degenerative disorder, will be available this year for the first time on the NHS in England.
Zolgensma, which costs £1.79m per dose, halts the progression of spinal muscular atrophy (SMA), which involves loss of movement, muscle weakness and paralysis, and is the leading genetic cause of death in infants.
Up to 80 infants a year in England are expected to benefit from the drug, which is administered as a single dose and replaces the function of the faulty SMN1 gene. The active ingredient, onasemnogene abeparvovec, restores the gene and produces proteins essential for muscle movement and nerve function. ....

United Kingdom , Francesco Muntoni , Sally Anne Tsangarides , Meindert Boysen , Simon Stevens , National Institute For Health , National Institute , Care Excellence , Sir Simon Stevens , Novartis Gene Therapies , Great Ormond Street , ஒன்றுபட்டது கிஂக்டம் , சிமோன் ஸ்டீவன்ஸ் , தேசிய நிறுவனம் க்கு ஆரோக்கியம் , தேசிய நிறுவனம் , பராமரிப்பு சிறப்பானது , ஐயா சிமோன் ஸ்டீவன்ஸ் , நோவர்த்திச் கீந் சிகிச்சைகள் , நன்று ஆர்‌மஂட் தெரு ,